|

Tacabrutideg Clinical Trials

5 actively recruiting trials across 4 locations

Also known as: BGB-16673

Pipeline

Phase 2: 1Phase 3: 2Phase 1/2: 2

Top Sponsors

  • BeOne Medicines4
  • Massachusetts General Hospital1

Indications

  • Cancer5
  • Chronic Lymphocytic Leukemia4
  • B-cell Malignancy2
  • Small Lymphocytic Lymphoma2
  • Waldenström Macroglobulinemia1

Birmingham, Alabama2 trials

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

University of Alabama At Birmingham Hospital

Phase 1/2
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

University of Alabama At Birmingham Hospital

Phase 3

Phoenix, Arizona1 trial

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Mayo Clinic Phoenix

Phase 1/2

Jonesboro, Arkansas1 trial

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

St Bernards Medical Center

Phase 3

Boston, Massachusetts1 trial

Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

Massachusetts General Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.